

1 **Effects of Side-Effect Risk Framing Strategies on**
2 **COVID-19 Vaccine Intentions: A Randomized Controlled Trial**

3
4 Nikkil Sudharsanan^{1*}, Caterina Favaretti², Violetta Hachaturyan²,
5 Till Bärnighausen², Alain Vandormael²

6
7 ¹Assistant Professorship of Behavioral Science for Disease Prevention and Health Care, Technical
8 University of Munich, Munich, Germany.

9 ²Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.

10

11 *Corresponding author: Nikkil Sudharsanan

12 **Email:** nikkil.sudharsanan@tum.de

13 **Abstract**

14 Fear over side-effects is one of the main drivers of COVID-19 vaccine hesitancy. We conducted a
15 pre-registered randomized controlled trial among 8998 individuals to examine the effects of different
16 ways of framing and presenting vaccine side-effects on individuals' willingness to get vaccinated. We
17 found that adding a descriptive risk label ("very low risk") next to the numerical side-effect and
18 providing a comparison to motor vehicle mortality increased participants' willingness to take the
19 COVID-19 vaccine by 3.0 percentage points ($p = 0.003$) and 2.4 percentage points ($p = 0.049$),
20 respectively. These effects were independent and additive and combining both framing strategies
21 increased willingness to receive the vaccine by 6.1 percentage points ($p < 0.001$). Mechanistically, we
22 find evidence that these framing effects operate by increasing individuals' perceptions of how safe the
23 vaccine is. Our results reveal that low-cost side-effect framing strategies can meaningfully affect
24 vaccine intentions at a population level.

25

26 **Keywords:** COVID-19, risk communication, heuristics, vaccine hesitancy, randomized controlled
27 trial, public health

28 Introduction

29 Vaccination is one of the main strategies for controlling the COVID-19 pandemic. However,
30 vaccination rates have slowed and are far from target levels in countries like the United States and the
31 United Kingdom. For example, in the United States, the share of the population that is fully vaccinated
32 went from 1.8% in February 2021 to 40.4% in May 2021 but has since only risen to 54% in the
33 following four months (1). While not as stagnant, there is a similar pattern in the United Kingdom,
34 where the share of the population that is fully vaccinated was just 65.6% as of September 27th, 2021
35 (1). These vaccination trends are insufficient to prevent the spread of COVID-19, especially the Delta-
36 variant, which has re-ignited the pandemic in both countries (1–3).

37 Vaccine hesitancy is not the result of a single homogenous cause and can vary for different
38 individuals and population groups. For example, recent studies have identified several potential
39 reasons for COVID-19 vaccine hesitancy, including a low perceived risk of COVID-19 infection and
40 concern around how quickly the vaccines were developed (4–7). A common finding across these
41 studies is that fear and concern about vaccine side-effects is an important reason for vaccine hesitancy.
42 These concerns were potentially heightened by widespread media coverage of vaccine side-effects in
43 April and May 2021, along with the pausing of vaccination efforts in several countries due to this
44 media coverage (8, 9). Although COVID-19 vaccine side-effects rates are extremely low (1 per 100,000
45 people vaccinated with AstraZeneca in the European Union) (10), these rates were often presented
46 by the media without context (9, 11–13), likely leading some individuals to reject vaccine uptake (14).
47 In addition, the pausing of global COVID-19 vaccination efforts may have sent a strong signal that
48 side effects are a major cause of concern, thus increasing vaccine hesitancy.

49 Addressing public concerns over vaccine side-effects will be a key component of efforts to
50 improve vaccine use in the United States, United Kingdom, and globally -- especially as new vaccines
51 are released. There is a large body of evidence in the health communication and the behavioral sciences

52 that shows that how risks are framed and presented to individuals can affect their perceptions of its
53 severity and ultimately their behavior (15–17). For example, studies have shown that whether
54 numerical risks are presented as percentages or natural frequencies (e.g. 1% compared to 1 out of
55 100), with a comparison to a commonly understood but different risk (e.g. the risk of motor-vehicle
56 mortality), using infographics (e.g. visually showing the numbers of individuals in the numerator and
57 denominator of a risk), with descriptive labels (e.g. putting “very low risk” or “high risk” next to the
58 numerical risk) can all influence behavior. Therefore, simple changes to the framing of COVID-19
59 vaccine side-effect risks may have a meaningful influence on the number of people who choose to get
60 vaccinated. Such “nudges” are viewed positively by policymakers since they are often affordable to
61 implement and have the potential for wide-population reach (18).

62 These types of framing effects do not affect behavior by changing deeply held attitudes and
63 beliefs, or by creating strong incentives for a certain behavior. Rather, research has shown that
64 individuals have a limited cognitive ability to process and internalize risk information, especially rare
65 risks like COVID-19 side-effects, and that individuals use mental guides or “heuristics” to make sense
66 of risk information that ultimately guides their decisions (19–21). Therefore, framing effects work by
67 modifying the heuristics that individuals use to understand a risk in a way that does not strongly affect
68 their incentives or remove their agency.

69 What remains unknown to date, however, is what the effect of such framing effects are on
70 COVID-19 vaccine intentions, which framing strategies are most promising, and whether such nudges
71 can even influence COVID-19 vaccination behavior. Given that vaccination has become socially and
72 politically charged, affecting hesitancy may no longer be amenable to light-touch nudge and framing
73 interventions. Relatedly, it is an open question whether such framing effects will still be effective given
74 that individuals have already experienced months of side-effect-related media coverage.

75 To answer these questions, we conducted a randomized controlled trial evaluating the effect
76 of three framing strategies on COVID-19 vaccine intentions among 8988 adults ages 18+ (4502 adults
77 in the United States and 4496 in the United Kingdom). We presented participants information on a
78 hypothetical “future COVID-19 vaccine” including information on its side-effect rate (we chose a
79 side-effect rate that was comparable to the current vaccines) (22, 23). We examined three side-effect
80 framing strategies: what is the effect of adding a qualitative risk label next to the numerical risk, what
81 is the effect of adding a comparison group (along with which comparison group is most effective),
82 and for those with comparison groups, what is the effect of framing the comparison in relative rather
83 than absolute terms (absolute comparisons of small risks may be cognitively harder for individuals to
84 process than relative comparisons). Based on a pre-registered and published analysis plan (24), we
85 then evaluated the effect of these framing strategies on two outcomes: self-reported willingness to
86 take the hypothetical vaccine, and as a measure of the mechanism of our framing effects, individuals’
87 perceived safety of the vaccine.

88

89 **Results**

90 *Effects of vaccine side-effect framing strategies on COVID-19 vaccine intentions*

91 Figure 1 presents the results of the three main framing strategies on the proportion of participants
92 that report that they would take the hypothetical vaccine (the results are presented on the percentage
93 point scale). Among all the strategies, we find that adding a simple qualitative risk label (“very low
94 risk”) next to the numerical risk increased vaccine intentions by 3.0 percentage points (95% CI: 1.0,
95 4.9; $p = 0.003$; control group mean: 65%). For our two comparison strategies, we found that adding
96 a comparison to motor-vehicle mortality (Effect size: 2.4 percentage points; 95% CI: 0.001, 4.7; $p =$
97 0.049; control group mean: 65%) had an impact on vaccine intentions but no evidence of an effect of
98 adding a comparison to COVID-19 mortality (Effect size: 0.8 percentage points; 95% CI: -1.6, 3.2; p

99 = 0.496; control group mean: 65%). This is a surprising result as we expected the comparison to
100 COVID-19 mortality to be more salient both because it is substantially higher than motor-vehicle
101 mortality and because it is the form of mortality directly related to vaccination. In the US, for example,
102 motor vehicle mortality in 2020 was 12 per 100,000 population while COVID-19 mortality in the same
103 year was 170 per 100,000 population. Lastly, going against our expectation, we did not find evidence
104 that relative, compared to absolute, framings of comparisons had a large impact on willingness to take
105 the hypothetical future COVID-19 vaccine (Effect size: 1.3 percentage points; 95% CI: -1.1, 3.6; $p =$
106 0.285; control group mean: 67%).

107 Figure 1 also presents the effect of the strategies on participants' perceptions of how safe the
108 vaccine is (measured on a scale of 1-10). This secondary outcome serves to investigate whether the
109 effects we observed on vaccine intentions were driven through perceptions of safety (providing more
110 information may affect vaccine intentions, for example, by increasing individuals' trust in the source
111 of information rather than directly affecting their perceptions of vaccine safety). Although the
112 magnitude of the effect sizes is small, we find that the pattern of the framing effects on perceptions
113 of vaccine safety closely mirrors the primary effects on willingness to take the vaccine. This suggests
114 that perceptions of safety are indeed one of the pathways through which these framing effects operate,
115 although our analyses do not exclude the possibility that by providing more information, these framing
116 strategies also affect vaccine intentions by increasing the perceived trustworthiness or reliability of the
117 information.

118

119 *Are the two effects substitutes, additive, or synergistic?*

120 An important question is how effective these strategies are when combined. For example, it could be
121 the case that vaccine intentions are only movable by a fixed margin, such that even when both
122 qualitative risk labels and comparison groups are used, the resulting change in vaccine intentions is

123 less than the sum of the independent effects. Conversely, the effects may be synergistic such that
124 combining strategies leads to larger effects than the sum of the independent effects. To assess this
125 consideration, in a non-pre-registered analysis, we estimated the effect of adding both a qualitative risk
126 label and comparison to motor vehicle mortality on willingness to take the hypothetical COVID-19
127 vaccine (Table 1). We find that at a minimum, the effects are independent and additive, with some
128 indication that they may even be synergistic. Compared to those that received neither a quality risk
129 label nor a comparison risk (N = 1499; control mean: 63%), those that received both strategies were
130 6.1 percentage points (95% CI: 2.8, 9.5; $p < 0.001$) more likely to state that they would take the vaccine.

131

132 *Differences by country, sex, and age group*

133 Figure 2 examines whether the effects of these framing strategies vary by country, age, and sex. The
134 coefficients in each figure show the interaction effect on the treatment with the main heterogeneity
135 characteristic and are thus interpreted as how much larger is the framing effect for a particular group
136 compared to another on the log-odds scale. There are several reasons to suspect that there may be
137 differences in the magnitude of framing effects across groups. Contexts where vaccines have become
138 highly politicized like the US may be less responsive to framing effects than in places like the UK.
139 Older individuals may use different heuristics for assessing risk and thus respond differently to framing
140 effects (although the direction of this is theoretically ambiguous); and on average, men and women
141 may have different risk thresholds for what they deem to be risky or not (25–27), which may affect
142 how the framing effects impact behavior.

143 We do not find evidence that the framing strategies vary across country, age, or sex.
144 Importantly, due to our sample sizes, we cannot rule out the possibility of potentially small interaction
145 effects. Therefore, our results should be interpreted as not finding evidence for any large differences.

146

147 ***Robustness***

148 We find no evidence of imbalances in sociodemographic characteristics across the experimental
149 groups (Supplemental Tables S1-S3) and our main results remain unchanged after excluding these
150 characteristics as control variables in the main regression analyses (Supplemental Table S4). Our results
151 are also consistent when we use linear probability rather than logistic regression models (Supplemental
152 Table S4) and when we examine the outcome as a four-category ordinal (rather than binary) variable
153 (Supplemental Table S5).

154

155 **Discussion**

156 We found that adding a simple descriptive risk label (“very low risk”) next to the numerical side-effect
157 increased participants’ willingness to take the COVID-19 vaccine by 3.0 percentage points ($p = 0.003$).
158 Providing a comparison to motor vehicle mortality increased COVID-19 vaccine willingness by 2.4
159 percentage points ($p = 0.049$). Importantly, we found that these effects were independent and additive:
160 participants that received both a qualitative risk label and comparison to motor-vehicle mortality were
161 6.1 percentage points ($p < 0.001$) more likely to report willingness to take a vaccine compared to those
162 who did not receive a label or comparison. This is an important and meaningful effect at the
163 population level, where even small changes in vaccination rates can have large health consequences
164 (28). These results are especially reassuring considering the low cost and ease of implementing such
165 framing strategies. Based on the effects on perceptions of vaccine safety, we find support for the
166 hypothesis that these effects work by modifying individuals’ judgments about how safe the vaccine is.
167 Taken together, our results reveal that despite increasingly strong vaccination hesitancy and exposure
168 to large amounts of vaccine information, low-cost side-effect framing strategies can meaningfully
169 affect vaccination intentions at a population level. Given that vaccination for COVID-19 will likely

170 remain an important priority for the foreseeable future, these insights can be valuable for increasing
171 the uptake of future vaccination efforts.

172

173 **Materials and Methods**

174 *Study Approvals, Registration, and Pre-Analysis Plan*

175 Prior to recruiting any participants, we received ethical approval for the study from the Medical Faculty
176 of Heidelberg University Ethics Committee (#S-443/2021), registered the trial, including the
177 outcomes and treatments, on the German Clinical Trials Registry (#DRKS00025551), and published
178 a trial protocol with a pre-analysis plan (24). All the analyses and results we present here are in line
179 with our pre-analysis plan.

180 The study here is missing one secondary sub-analysis that we registered as part of the protocol
181 and pre-analysis plan. This additional analysis was intended to be based on a comparison of the main
182 study participants (the 8998 individuals who form the current study) to an additional 3000 participants.
183 The reason for the omission of this sub-analysis is that there was an error in the study text for these
184 additional 3000 participants. This error, however, had no impact on the 8998 participants recruited
185 for the main study presented here, and as stated in our pre-analysis plan, this omitted analysis was only
186 intended as a supplementary analysis.

187

188 *Study Population, Eligibility, Inclusion, and Exclusion Criteria*

189 This was an online-based randomized controlled trial study. To be enrolled in the trial, participants
190 had to meet the following inclusion criteria be 18 years or older, have current residence in the United
191 States or the United Kingdom, and be able to speak English. Participants who did not meet the
192 inclusion criteria were not eligible to participate and were excluded from the study.

193

194 ***Participant Recruitment***

195 We used Prolific (29), an online-based service for recruiting participants for online-based research
196 studies to recruit the study participants. Prolific participants are paid for their participation (we paid
197 each participant £0.63/\$0.88 for the expected 5-minute completion time). Within Prolific, we used a
198 stratified quota sampling procedure to match the education distribution of our sample to the general
199 population (stratified by sex and country) based on available data for each country (30,31). We aimed
200 to recruit a total of 9000 total participants, split evenly by country and sex. 99% of our participants
201 were recruited between 30 July 2021 and 10 August 2021. To reach our target quotas by sex and
202 education, the final 1% of participants were recruited between 11 August 2021 and 4 October 2021.

203

204 ***Description of the Experiment***

205 We previously published the protocol for our trial with a description of the experiment (24). On the
206 Prolific platform, potential participants were provided information that the aim of the study was to
207 understand their willingness to take COVID-19 vaccines, the risks and benefits of the study, and how
208 they could contact the researcher (and/or the human subjects review board at the Heidelberg
209 University). After consenting on Prolific, participants were redirected to the Gorilla platform, an
210 interactive web-based service for conducting behavioral science experiments. On the Gorilla page, we
211 provided additional information on data protection. For participants that agreed to participate, we first
212 collected basic sociodemographic information and then set up the experiment by telling participants
213 that we are going to show them information on a hypothetical future COVID-19 vaccine and would
214 like to know how willing they would be to take it. At this stage, we emphasized that their answers
215 cannot be linked back to them in any way. Participants were then presented information on the vaccine
216 and its side effect rate on a single page. The main experimental component was how the vaccine side
217 effect rate was presented to participants.

218

219 *Randomization*

220 We used a factorial randomization design to assign participants to three main factors. Factor 1 was
221 whether there was a qualitative risk label saying “very low risk” next to the numerical risk or not.
222 Factor 2 was whether the risk was presented with no comparison, a comparison to motor-vehicle
223 mortality, or a comparison to COVID-19 mortality. Factor 3 was only among that received a
224 comparison risk and varied whether the comparison was presented in an absolute or relative way. We
225 randomized participants to each factor independently (stratified by country), such that, for example,
226 which comparison group a participant received did not depend on whether they received a risk label
227 or not. This means that the proportion of participants that received a risk label will be balanced across
228 the treatment groups for the comparison risks. We repeated this independent randomization
229 procedure for whether the comparison risk is presented as an absolute or relative comparison among
230 the 2/3rds of the sample that were randomized to receive any comparison risk. Similarly, this means
231 that conditional on receiving any comparison risk (either motor vehicle or COVID-19 mortality), the
232 proportion of participants that received each type of comparison, and the proportion that received a
233 labeled risk will be balanced across the treatment groups for absolute and relative framings. Note that
234 in practice, the Gorilla algorithm handled the randomization using a stratified randomization approach
235 to prevent chance imbalances in the joint distribution of the factors.

236

237 *Outcomes*

238 Our main outcome was a binary variable for whether participants reported “yes” to the question of
239 “Would you take this vaccine if it were made available to you?” Importantly we asked participants to
240 answer as if they had not been vaccinated even if they already received some form of vaccination. In
241 the Supplemental Table S5, we show the main study results using a four-category ordinal response

242 rather than a binary response variable and find no change to our conclusions. Our secondary outcome
243 was participants' perception of how safe the vaccine is, based on a scale of 1 (extremely unsafe) to 10
244 (extremely safe). This secondary outcome served to determine if the effects we saw on vaccine
245 willingness were at least partly driven through perceptions and judgments of the vaccine's safety.

246

247 **Data and Code Availability**

248 The datasets generated during and/or analysed during the current study and the analysis codes used
249 to produce the figures and tables are available in the Open Science Framework repository,
250 <https://doi.org/10.17605/OSF.IO/HQNKR>.

251

252 **Acknowledgments**

253 None.

254

255 **Author Contributions:** NS wrote the manuscript. NS and AV designed the trial and developed the
256 questionnaires. NS, AV, CF, and VH carried out the experiment. NS performed the analysis. All
257 authors read and approved the final manuscript.

258

259 **Competing Interest Statement:** The authors declare that they have no competing interests.

260 References

- 261 1. H. Ritchie, E. Ortiz-Ospina, D. Beltekian, E. Mathieu, J. Hasell, B. Macdonald, C. Giattino, C.
262 Appel, L. Rodés-Guirao, M. Roser, Coronavirus Pandemic (COVID-19). *Our World in Data*
263 (2021), (available at <https://ourworldindata.org/coronavirus>).
- 264 2. GOV.UK, Variants: distribution of case data, 17 September 2021, (available at
265 [https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-](https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-17-september-2021)
266 [case-numbers/variants-distribution-of-case-data-17-september-2021](https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-17-september-2021)).
- 267 3. Centers for Disease Control and Prevention, COVID Data Tracker (2020), (available at
268 <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>).
- 269 4. J. Aw, J. J. B. Seng, S. S. Y. Seah, L. L. Low, COVID-19 Vaccine Hesitancy—A Scoping
270 Review of Literature in High-Income Countries. *Vaccines*. **9**, 900 (2021).
271 doi:10.3390/vaccines9080900.
- 272 5. E. Robertson, K. S. Reeve, C. L. Niedzwiedz, J. Moore, M. Blake, M. Green, S. V. Katikireddi,
273 M. J. Benzeval, Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal
274 study. *Brain, Behavior, and Immunity*. **94**, 41–50 (2021). doi:10.1016/j.bbi.2021.03.008.
- 275 6. J. Griffith, H. Marani, H. Monkman, COVID-19 Vaccine Hesitancy in Canada: Content
276 Analysis of Tweets Using the Theoretical Domains Framework. *J Med Internet Res*. **23**, e26874
277 (2021). doi:10.2196/26874.
- 278 7. S. Machingaidze, C. S. Wiysonge, Understanding COVID-19 vaccine hesitancy. *Nat Med*. **27**,
279 1338–1339 (2021). doi:10.1038/s41591-021-01459-7.
- 280 8. M. Davey, What does Australia’s new advice on the AstraZeneca Covid vaccine mean and
281 what is the risk? *The Guardian* (2021), (available at
282 [https://www.theguardian.com/business/2021/apr/09/astrazeneca-vaccine-australia-covid-](https://www.theguardian.com/business/2021/apr/09/astrazeneca-vaccine-australia-covid-new-advice-side-effects-how-high-is-risk-blood-clots)
283 [new-advice-side-effects-how-high-is-risk-blood-clots](https://www.theguardian.com/business/2021/apr/09/astrazeneca-vaccine-australia-covid-new-advice-side-effects-how-high-is-risk-blood-clots)).


- 284 9. B. Mueller, M. Eddy, Possible Side Effects of AstraZeneca Vaccine Come Into Sharper Focus.
285 *The New York Times* (2021), (available at
286 [https://www.nytimes.com/2021/04/06/world/europe/astrazeneca-side-effects-vaccine-](https://www.nytimes.com/2021/04/06/world/europe/astrazeneca-side-effects-vaccine-covid.html)
287 [covid.html](https://www.nytimes.com/2021/04/06/world/europe/astrazeneca-side-effects-vaccine-covid.html)).
- 288 10. World Health Organization, Global Advisory Committee on Vaccine Safety (GACVS) review
289 of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19
290 Vaccine (Vaxzevria and Covishield). *WHO* (2021), (available at
291 [https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-](https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield))
292 [\(gacvs\)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-](https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield))
293 [covid-19-vaccine-\(vaxzevria-and-covishield\)](https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield))).
- 294 11. P. Karp, Australia reports second blood clot case ‘likely’ linked to AstraZeneca Covid vaccine.
295 *The Guardian* (2021), (available at [https://www.theguardian.com/australia-](https://www.theguardian.com/australia-news/2021/apr/13/australia-reports-second-blood-clot-case-likely-linked-to-astrazeneca-covid-vaccine)
296 [news/2021/apr/13/australia-reports-second-blood-clot-case-likely-linked-to-astrazeneca-](https://www.theguardian.com/australia-news/2021/apr/13/australia-reports-second-blood-clot-case-likely-linked-to-astrazeneca-covid-vaccine)
297 [covid-vaccine](https://www.theguardian.com/australia-news/2021/apr/13/australia-reports-second-blood-clot-case-likely-linked-to-astrazeneca-covid-vaccine)).
- 298 12. K. Rivas, More blood clot cases following Johnson & Johnson COVID-19 vaccine reported
299 (2021), (available at [https://www.foxnews.com/health/more-blood-clot-cases-johnson-](https://www.foxnews.com/health/more-blood-clot-cases-johnson-johnson-covid-19-vaccine-reported)
300 [johnson-covid-19-vaccine-reported](https://www.foxnews.com/health/more-blood-clot-cases-johnson-johnson-covid-19-vaccine-reported)).
- 301 13. R. Saunt, Mother-of-three, 47, dies after AstraZeneca Covid jab caused blood clots on her
302 brain which led to a stroke. *Daily Mail Online* (2021), (available at
303 [https://www.dailymail.co.uk/news/article-9732583/Mother-three-47-dies-AstraZeneca-](https://www.dailymail.co.uk/news/article-9732583/Mother-three-47-dies-AstraZeneca-Covid-jab-caused-blood-clots-brain.html)
304 [Covid-jab-caused-blood-clots-brain.html](https://www.dailymail.co.uk/news/article-9732583/Mother-three-47-dies-AstraZeneca-Covid-jab-caused-blood-clots-brain.html)).
- 305 14. M. Pinna, L. Picard, C. Goessmann, Cable News and COVID-19 Vaccine Compliance. *SSRN*
306 *Journal* (2021), doi:10.2139/ssrn.3890340. doi:10.2139/ssrn.3890340.

- 307 15. C. Bonner, L. J. Trevena, W. Gaissmaier, P. K. J. Han, Y. Okan, E. Ozanne, E. Peters, D.
308 Timmermans, B. J. Zikmund-Fisher, Current Best Practice for Presenting Probabilities in
309 Patient Decision Aids: Fundamental Principles. *Med Decis Making*. **41**, 821–833 (2021).
310 doi:10.1177/0272989X21996328.
- 311 16. L. J. Trevena, B. J. Zikmund-Fisher, A. Edwards, W. Gaissmaier, M. Galesic, P. K. Han, J.
312 King, M. L. Lawson, S. K. Linder, I. Lipkus, E. Ozanne, E. Peters, D. Timmermans, S.
313 Woloshin, Presenting quantitative information about decision outcomes: a risk
314 communication primer for patient decision aid developers. *BMC Med Inform Decis Mak*. **13**, S7
315 (2013).
- 316 17. D. A. Zipkin, C. A. Umscheid, N. L. Keating, E. Allen, K. Aung, R. Beyth, S. Kaatz, D. M.
317 Mann, J. B. Sussman, D. Korenstein, C. Schardt, A. Nagi, R. Sloane, D. A. Feldstein,
318 Evidence-Based Risk Communication: A Systematic Review. *Ann Intern Med*. **161**, 270 (2014).
319 doi:10.7326/M14-0295.
- 320 18. C. R. Sunstein, R. H. Thaler, *Nudge: Improving Decisions about Health, Wealth* (Yale University
321 Press, 2008).
- 322 19. A. Tversky, D. Kahneman, Judgment under Uncertainty: Heuristics and Biases: Biases in
323 judgments reveal some heuristics of thinking under uncertainty. *Science*. **185**, 1124–1131 (1974).
324 doi:10.1126/science.185.4157.1124.
- 325 20. G. Gigerenzer, W. Gaissmaier, Heuristic Decision Making. *Annu. Rev. Psychol*. **62**, 451–482
326 (2011), doi:10.1146/annurev-psych-120709-145346.
- 327 21. C. W. Trumbo, Information Processing and Risk Perception: An Adaptation of the Heuristic-
328 Systematic Model. *Journal of Communication*. **52**, 367–382 (2002). doi:10.1111/j.1460-
329 2466.2002.tb02550.x.

- 330 22. European Medicines Agency (EMA), AstraZeneca’s COVID-19 vaccine: benefits and risks in
331 context Share. *European Medicines Agency* (2021), (available at
332 <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context>).
- 333 23. Centers for Disease Control and Prevention, CDC Recommends Use of Johnson & Johnson’s
334 Janssen COVID-19 Vaccine Resume (2021), (available at
335 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html>).
- 336 24. N. Sudharsanan, C. Favaretti, V. Hachaturyan, T. Bärnighausen, A. Vandormael, The effect of
337 framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for
338 adults in the UK and the USA: A structured summary of a study protocol for a randomized
339 controlled trial. *Trials*. **22**, 592 (2021). doi:10.1186/s13063-021-05484-2.
- 340 25. C. R. Harris, M. Jenkins, Gender differences in risk assessment: why do women take fewer
341 risks than men? (2006).
- 342 26. M. L. Finucane, P. Slovic, C. K. Mertz, J. Flynn, T. A. Satterfield, Gender, race, and perceived
343 risk: The “white male” effect. *Health, Risk & Society*. **2**, 159–172 (2000).
344 doi:10.1080/713670162.
- 345 27. A. Alsharawy, R. Spoon, A. Smith, S. Ball, Gender Differences in Fear and Risk Perception
346 During the COVID-19 Pandemic. *Front. Psychol.* **12**, 689467 (2021).
347 doi:10.3389/fpsyg.2021.689467.
- 348 28. H. M. Scobie, A. G. Johnson, A. B. Suthar, R. Severson, N. B. Alden, S. Balter, D. Bertolino,
349 D. Blythe, S. Brady, B. Cadwell, I. Cheng, S. Davidson, J. Delgadillo, K. Devinney, J. Duchin,
350 M. Duwell, R. Fisher, A. Fleischauer, A. Grant, J. Griffin, M. Haddix, J. Hand, M. Hanson, E.
351 Hawkins, R. K. Herlihy, L. Hicks, C. Holtzman, M. Hoskins, J. Hyun, R. Kaur, M. Kay, H.
352 Kidrowski, C. Kim, K. Komatsu, K. Kugeler, M. Lewis, B. C. Lyons, S. Lyons, R. Lynfield, K.
353 McCaffrey, C. McMullen, L. Milroy, S. Meyer, L. Nolen, M. R. Patel, S. Pogosjans, H. E.

- 354 Reese, A. Saupe, J. Sell, T. Sokol, D. Sosin, E. Stanislawski, K. Stevens, H. Vest, K. White, E.
355 Wilson, A. MacNeil, M. D. Ritchey, B. J. Silk, Monitoring Incidence of COVID-19 Cases,
356 Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17,
357 2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 1284–1290 (2021).
358 doi:10.15585/mmwr.mm7037e1.
- 359 29. Prolific (2021), (available at <https://www.prolific.co/>).
- 360 30. U.S. Census Bureau, Educational Attainment in the United States: 2019. *The United States*
361 *Census Bureau* (2020), (available at
362 [https://www.census.gov/data/tables/2019/demo/educational-attainment/cps-detailed-](https://www.census.gov/data/tables/2019/demo/educational-attainment/cps-detailed-tables.html)
363 [tables.html](https://www.census.gov/data/tables/2019/demo/educational-attainment/cps-detailed-tables.html)).
- 364 31. OECD, *Education at a Glance 2021: OECD Indicators* (OECD, 2021), *Education at a Glance*,
365 doi:10.1787/b35a14e5-en.


366 **Figures and Tables**



367

368 **Figure 1.** Effect of the vaccine side-effect framing strategies on the probability that participants report
369 that they would take the hypothetical vaccine and their perceptions of how safe the hypothetical
370 vaccine is (N = 8998 for Strategy 1 and 2); Strategy 3 is estimated only among those that received a
371 comparison risk (N = 5998). Control means for strategies 1 and 2 are 65% and 67% for strategy 3.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



372

373 **Figure 2.** Differences in the framing effects by country, age, and sex. Coefficients are the interaction

374 effect of the main heterogeneity characteristic with the indicator for each treatment strategy and are

375 presented as coefficients on the log-odds scale from logistic regression models.

Table 1. Independent and combined effects of risk labeling and motor-vehicle mortality comparisons on willingness to take a hypothetical COVID-19 vaccine.

	Effect Size (percentage points)	p-value
Effect of risk labeling (ref: no risk label) <i>N</i> = 8998	3.0	0.003
Effect of motor-vehicle comparison (ref: no comparison) <i>N</i> =8998	2.4	0.049
Effect of both risk labeling and a motor-vehicle comparison (ref: no risk label nor comparison) <i>N</i> =3002	6.1	<0.001

Notes: Outcome: "Would you take this vaccine?" (yes =1, others = 0). As per our pre-analysis plan, all regressions include covariates for age, sex, education, and country. Sample sizes for the relative to absolute comparison and effect of both labeling and a motor-vehicle mortality comparison are smaller since they are only estimated among subset of the total sample. P-values are from two-tailed t-tests.